In the original version of this article (1), two references that provide details about the mice used for the study were omitted within the Results section. In the subsection titled “Establishment of Brca1-deficient and Brca1-WT TNBC Mouse Models” on page 356, a citation to ref. 2 (below) has been added at the end of the following sentence: “We generated two cohorts of mice to model both BRCA1-germline mutation carriers and sporadic TNBCs: K14cre; Trp53flox/flox; Brca1flox/flox, defined as Brca1-deficient cohort; and K14cre; Trp53flox/flox; Brca1wt/wt, defined as Brca1 wild-type (WT) cohort (Supplementary Fig. S1A).” In the subsection “Tumors Harboring FGFR2 Fusion Proteins Are Responsive to FGFR2 Inhibition In Vivo, Resulting in Complete Tumor Regression” on page 361, a citation to ref. 3 (below) has been added at the end of the following sentence: “To this end, we transplanted mouse TNBC tumors with identifiable potential genetic drivers in cohorts of nude mice.” The references have been updated in the latest online HTML and PDF versions of the article. The authors regret this error.

1.
Liu
H
,
Murphy
CJ
,
Karreth
FA
,
Emdal
KB
,
White
FM
,
Elemento
O
, et al
Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer
.
Cancer Discov
2018
;
8
:
354
69
.
2.
Liu
X
,
Holstege
H
,
van der Gulden
H
,
Treur-Mulder
M
,
Zevenhoven
J
,
Velds
A
, et al
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer
.
Proc Natl Acad Sci U S A
2007
;
104
:
12111
6
.
3.
Rottenberg
S
,
Jaspers
JE
,
Kersbergen
A
,
van der Burg
E
,
Nygren
AO
,
Zander
SA
, et al
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
.
Proc Natl Acad Sci U S A
2008
;
105
:
17079
84
.